A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
A Phase Ib, Open-Label Study of The Safety and Pharmacology of Atezolizumab (Anti PD-L1 Antibody) Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With BRAFV600-Mutation Positive Metastatic Melanoma
Sponsor: Genentech, Inc.
This PHASE1 trial investigates Malignant Melanoma and is currently completed. Genentech, Inc. leads this study, which shows 19 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
19 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 14 earlier versions
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
-
Dec 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
-
Oct 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
-
Jul 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE1
-
Apr 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Aug 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
May 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1
-
Mar 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Aurora, United States
- • Boston, United States
- • Houston, United States
- • Los Angeles, United States
- • Nashville, United States
- • Sarasota, United States